Lodoxamide

Identification

Summary

Lodoxamide is an ophthalmic agent used for the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

Brand Names
Alomide
Generic Name
Lodoxamide
DrugBank Accession Number
DB06794
Background

Lodoxamide is a mast-cell stabilizer for topical administration into the eye. Mast-cell stabilizers, first one approved being cromolyn sodium, are used in treatment of ocular hypersensitivity reactions such as vernal conjunctivitis. These conditions often require treatment with anti-inflammatory medications such as ophthalmic NSAIDs or topical steroids which may cause systemic or toxic effects long-term. Although less effective than topical steroids at decreasing inflammation, mast-cell stabilizers offer another treatment option and exhibit minimal adverse effects. Lodoxamide is marketed under the brand name Alomide by Alcon.

Type
Small Molecule
Groups
Approved
Structure
Thumb
Weight
Average: 311.63
Monoisotopic: 310.9945126
Chemical Formula
C11H6ClN3O6
Synonyms
  • Lodoxamida
  • Lodoxamide
  • N,N'-(2-chloro-5-cyano-m-phenylene)dioxamate
External IDs
  • U-42585E

Pharmacology

Indication

Indicated in the treatment of the ocular disorders referred to by the terms vernal keratoconjunctivitis, vernal conjunctivitis, and vernal keratitis.

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Lodoxamide is a mast cell stabilizer that inhibits the in vivo Type 1 immediate hypersensitivity reaction. Lodoxamide therapy inhibits the increases in cutaneous vascular permeability that are associated with reagin or IgE and antigen-mediated reactions.

Mechanism of action

Although lodoxamide's precise mechanism of action is unknown, it is postulated that it prevents calcium influx into mast cells upon antigen stimulation and therefore stabilizes the membrane. By stabilizing the mast cell membrane from degranulation, lodoxamide consequently inhibits the release of intracellular histamine and other chemoattractant factors that primarily cause ocular symptoms. Lodoxamide's mechanism of action may be similar to cromolyn sodium, as both exhibit cross-tachyphylaxis.

Absorption

In a study of twelve healthy adult volunteers, topical administration of lodoxamide tromethamine ophthalmic solution 0.1%, one drop in each eye four times per day for ten days, did not result in any measurable lodoxamide plasma levels at a detection limit of 2.5 ng/mL.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Urinary excretion is the major route of elimination.

Half-life

Elimination half-life was 8.5 hours in urine.

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
No interactions found.

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Lodoxamide tromethamine50LV9A548L63610-09-3JJOFNSLZHKIJEV-UHFFFAOYSA-N
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
AlomideSolution0.1 % w/vOphthalmicNovartis1992-12-31Not applicableCanada flag
AlomideSolution / drops1 mg/1mLOphthalmicALCON LABORATORIES, INC.1993-09-30Not applicableUS flag

Categories

ATC Codes
S01GX05 — Lodoxamide
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Anilides / N-arylamides / Benzonitriles / Chlorobenzenes / Dicarboxylic acids and derivatives / Aryl chlorides / Secondary carboxylic acid amides / Nitriles / Carboxylic acids / Organopnictogen compounds
show 4 more
Substituents
Alpha-amino acid or derivatives / Anilide / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Benzenoid / Benzonitrile / Carbonitrile / Carbonyl group / Carboxamide group
show 17 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
SPU695OD73
CAS number
53882-12-5
InChI Key
RVGLGHVJXCETIO-UHFFFAOYSA-N
InChI
InChI=1S/C11H6ClN3O6/c12-7-5(14-8(16)10(18)19)1-4(3-13)2-6(7)15-9(17)11(20)21/h1-2H,(H,14,16)(H,15,17)(H,18,19)(H,20,21)
IUPAC Name
{[3-(carboxyformamido)-2-chloro-5-cyanophenyl]carbamoyl}formic acid
SMILES
OC(=O)C(=O)NC1=CC(=CC(NC(=O)C(O)=O)=C1Cl)C#N

References

General References
  1. Avunduk AM, Avunduk MC, Kapicioglu Z, Akyol N, Tavli L: Mechanisms and comparison of anti-allergic efficacy of topical lodoxamide and cromolyn sodium treatment in vernal keratoconjunctivitis. Ophthalmology. 2000 Jul;107(7):1333-7. [Article]
  2. Lee S, Allard TR: Lodoxamide in vernal keratoconjunctivitis. Ann Pharmacother. 1996 May;30(5):535-7. [Article]
  3. Das D, Khan M, Gul A, Alam R: Safety and efficacy of lodoxamide in vernal keratoconjunctivitis. J Pak Med Assoc. 2011 Mar;61(3):239-41. [Article]
KEGG Drug
D04762
PubChem Compound
44564
PubChem Substance
310264890
ChemSpider
40543
BindingDB
50259889
RxNav
52151
ChEBI
135333
ChEMBL
CHEMBL1201266
ZINC
ZINC000002000707
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Lodoxamide
AHFS Codes
  • 52:02.00 — Antiallergic Agents
FDA label
Download (95.1 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SolutionOphthalmic0.1 % w/v
Solution / dropsOphthalmic
Solution / dropsOphthalmic1 mg/1mL
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0361 mg/mLALOGPS
logP0.72ALOGPS
logP0.83ChemAxon
logS-3.9ALOGPS
pKa (Strongest Acidic)-6.7ChemAxon
pKa (Strongest Basic)0.73ChemAxon
Physiological Charge-2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area156.59 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity69.9 m3·mol-1ChemAxon
Polarizability26.52 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on September 14, 2010 16:21 / Updated on May 14, 2021 11:41